27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
These findings suggest that sexual differentiation in early life has modest effects on adult development of AD in females, a relationship that appeared stronger in the context of APOE4 . 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our findings highlight the potential of diverse genomic backgrounds to uncover protective genetic factors, such as the African-specific protective PSG2 locus, found to confer a protective effect among APOE4 carriers. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In the colocalization of cis-eQTL and GWAS signals for Hispanics, we observed a high posterior probability (posterior prob = 0.9947) for the upstream gene variant rs755980338 on chromosome 11, which locally regulates EHD1 gene (GWAS p-value = 0.009, cis-eQTL p-value = 0.0041). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Fifty-four participants (~8% response rate) from the MindCrowd web-based cohort (mean age of 62.39 years; 39 females; and 23 APOE ε4 carriers) completed 75 trials of Super G. Results show that Super G performance was significantly associated with each of the targeted risk factors. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Spatial transcriptomics (ST) data provide spatially informed gene expression profiles. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Anti-amyloid treatment (AAT) with monoclonal antibodies represents a major therapeutic advance in early Alzheimer disease (AD), but its introduction has important and underappreciated implications for vascular neurology. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Diet and specific nutritional factors, alone and in combination with other lifestyle approaches, have an important role in decreasing the risk for dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study explores how older people with dementia and their family caregivers experience the process from diagnosis to follow-up in primary care, what support is needed, what works well and what could be improved. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Based on the stakeholder responses from fifteen providers and twenty community members, there was strong consensus in the need for local brain health services. 5 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Community-based participatory research (CBPR) offers effective, flexible approaches well suited to conduct health research with underrepresented populations that can be tailored to unique social, cultural, and geographic contexts. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
• Brain health depends on certain environmental resources of which socioeconomically disadvantaged people in particular are deprived. • Resource deprivation may increase dementia risk due to reduced attainment for deprived populations. • Improving attainment across the lifetime for disadvantaged individuals should be a public health priority for dementia prevention. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The unprecedented rise of artificial intelligence (AI) in recent times is unparalleled in history.AI 1 seemingly possesses cognitive abilities that hitherto only humans could boast of -reason, an inimitable, embodied, and finite existence. 47Nonetheless, the ubiquitous abilities of AI can help to enhance treatment and care for PLWDs in 48 enabling early diagnosis, continuous monitoring and personalized support. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Conventional dementia screening tools, whether paper tests or static artificial intelligence (AI) models, capture only a snapshot of cognition and need to be adminstered periodically. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The approval of disease-modifying treatments for Alzheimer's disease demands a rethinking of cognitive screening. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a progressive condition that affects cognitive and functional abilities. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This approach predicts clinical progression (2-year Clinical Dementia Rating Sum of Boxes change > 1) with an area under the curve of 0.836. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Data from the qualitative interviews will provide dyad preferences for intervention development. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
During alteplase administration, the patient experienced clinical deterioration. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We found that orientation, memory, and irritability scores were useful in predicting AD dementia onset, while daily living, depression, and executive function scores were identified as strong predictors in the LB cohort. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Amnestic mild cognitive impairment (aMCI) represents a critical prodromal stage of Alzheimer's disease (AD), yet effective therapeutic interventions to prevent or delay this conversion remain an unmet clinical need. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We consider the recent publication by Ornish and colleagues and the rigor expected for interventional clinical trials. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mild cognitive impairment (MCI) is primarily characterized by a gradual decline in cognitive function, where early detection and intervention are crucial to preventing Alzheimer's disease progression. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
MTX46943-mediated TREM2 activation leads to TREM2/DAP12 receptor complex formation and stabilizes surface location required for downstream signaling and microglia activation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The most notable effect sizes were observed in entropy for Beta1 and Beta3 bands in frontal regions for the DTS7 and DTS1 tasks, Beta2 relative power in C4 during DTAN, Theta modulation in the Theta and alpha-1 bands in frontal regions during DTS7, and Alpha2 modulations in the same task. 5 key findings →
Participants: 37 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The most notable effect sizes were observed in entropy for Beta1 and Beta3 bands in frontal regions for the DTS7 and DTS1 tasks, Beta2 relative power in C4 during DTAN, Theta modulation in the Theta and alpha-1 bands in frontal regions during DTS7, and Alpha2 modulations in the same task. 5 key findings →
Participants: 37 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →